Goldman Sachs Knock-Out CHKP/ DE000GQ8DA96 /
| 2024-05-29 10:20:25 AM | Chg.-0.60 | Bid10:00:34 PM | Ask10:00:34 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.16EUR | -34.09% | - Bid Size: - |
- Ask Size: - |
Check Point Software... | 136.2041 USD | 2078-12-31 | Call |
GlobeNewswire
05-29
DEADLINE ALERT for LUNA, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire
05-29
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
05-29
UPDATE -- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of L...
GlobeNewswire
05-29
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire
05-29
Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
GlobeNewswire
05-29
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immuno...
GlobeNewswire
05-29
Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Ph...
GlobeNewswire
05-29
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology...
GlobeNewswire
05-29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
05-29
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KI...
GlobeNewswire
05-29
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR ...
GlobeNewswire
05-28
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
05-28
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire
05-28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
05-28
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire
05-28
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire
05-27
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire
05-27
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
05-24
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenaden...
GlobeNewswire
05-23
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
05-23
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
